Integrating multiomics to elucidate the role of chromatin remodeling in glioma and the antitumor mechanisms and therapeutic potential of targeting LMNA - Report - MDSpire
Advertisement
Integrating multiomics to elucidate the role of chromatin remodeling in glioma and the antitumor mechanisms and therapeutic potential of targeting LMNA
Clinical Report: Utilizing Multiomics to Investigate Chromatin Remodeling's Impact on Glioma
Overview
This study identifies chromatin remodeling-related genes (CRRGs) in glioma and highlights LMNA as a potential prognostic biomarker and therapeutic target. The developed prognostic signature demonstrates robust clinical utility for risk stratification in glioma patients.
Background
Glioma is a highly aggressive brain tumor with poor clinical outcomes, necessitating the identification of effective prognostic tools and therapeutic targets. Chromatin remodeling plays a crucial role in tumorigenesis, yet its specific mechanisms in glioma are not fully understood. Understanding these mechanisms is vital for developing targeted therapies and improving patient outcomes.
Data Highlights
Finding
Details
CRRG Subtypes
Two CRRG-based subtypes identified, with Subgroup 2 showing better prognosis.
DECRRGs
28 glioma-specific DECRRGs were identified.
Prognostic Model
SuperPC-based model effectively stratified patients into high- and low-risk cohorts.
LMNA Role
LMNA depletion impaired tumor cell proliferation and invasion in vitro.
Natural Compounds
Four natural compounds identified as potential LMNA inhibitors through molecular docking.
Key Findings
Consensus clustering identified two CRRG-based glioma subtypes.
Patients in Subgroup 2 had significantly better prognoses.
28 DECRRGs were identified as glioma-specific.
LMNA was upregulated in glioma and correlated with poor survival.
LMNA depletion significantly reduced tumor cell proliferation and invasion.
Four natural compounds were identified as candidate LMNA inhibitors.
Clinical Implications
The CRRG-based prognostic signature can aid in risk stratification of glioma patients, potentially guiding treatment decisions. Targeting LMNA may offer a novel therapeutic strategy for improving outcomes in glioma treatment.
Conclusion
The findings underscore the importance of chromatin remodeling in glioma and position LMNA as a promising target for future therapeutic interventions.
